scholarly journals Tissue-Specific Differences in Brain Phosphodiesters in Late-Life Major Depression

2014 ◽  
Vol 22 (5) ◽  
pp. 499-509 ◽  
Author(s):  
David G. Harper ◽  
J. Eric Jensen ◽  
Caitlin Ravichandran ◽  
Yusuf Sivrioglu ◽  
Marisa Silveri ◽  
...  
2015 ◽  
Vol 207 (3) ◽  
pp. 235-242 ◽  
Author(s):  
M. Belvederi Murri ◽  
M. Amore ◽  
M. Menchetti ◽  
G. Toni ◽  
F. Neviani ◽  
...  

BackgroundInterventions including physical exercise may help improve the outcomes of late-life major depression, but few studies are available.AimsTo investigate whether augmenting sertraline therapy with physical exercise leads to better outcomes of late-life major depression.MethodPrimary care patients (>65 years) with major depression were randomised to 24 weeks of higher-intensity, progressive aerobic exercise plus sertraline (S+PAE), lower-intensity, non-progressive exercise plus sertraline (S+NPE) and sertraline alone. The primary outcome was remission (a score of $10 on the Hamilton Rating Scale for Depression).ResultsA total of 121 patients were included. At study end, 45% of participants in the sertraline group, 73% of those in the S+NPE group and 81% of those in the S+PAE group achieved remission (P = 0.001). A shorter time to remission was observed in the S+PAE group than in the sertraline-only group.ConclusionsPhysical exercise may be a safe and effective augmentation to antidepressant therapy in late-life major depression.


2004 ◽  
Vol 20 (6) ◽  
pp. 1039-1045 ◽  
Author(s):  
Nader Binesh ◽  
Anand Kumar ◽  
Sun Hwang ◽  
Jim Mintz ◽  
M. Albert Thomas

2013 ◽  
Vol 151 (1) ◽  
pp. 66-70 ◽  
Author(s):  
Hitoshi Maeshima ◽  
Hajime Baba ◽  
Yoshiyuki Nakano ◽  
Emi Satomura ◽  
Yuki Namekawa ◽  
...  

Author(s):  
Kevin J. Manning ◽  
Joshua Preciado‐Pina ◽  
Lihong Wang ◽  
Kimberly Fitzgibbon ◽  
Grace Chan ◽  
...  

1998 ◽  
Vol 8 ◽  
pp. S294
Author(s):  
A.V. Medvedey ◽  
M.J. Belova ◽  
A.I. Kolesnitshenko ◽  
A.N. Kurmishev ◽  
P.A. Tshebishev ◽  
...  

Author(s):  
Pat Arean ◽  
Eric Lenze ◽  
Joaquin A. Anguera

This chapter discusses how clinicians will need to prepare for a worldwide exponentially growing aging community by describing the current scope of practices with respect to the assessment and treatment mood disorders, including minor and major depression. Particularly for those in later life, the meaningful interpretation of standardized assessment scores requires consideration of medical and neurological complexities. Clinicians must be flexible not only with respect to characterization, but especially with respect to treatment, given the inherent challenges associated with access to care and the range of disability amongst these individuals. Indeed, these late-life individuals are typically assessed in a similar fashion to younger adults (which may obscure meaningful interpretations), making understanding the nuances underlying existing behavioral and pharmaceutical approaches an essential endeavor.


Sign in / Sign up

Export Citation Format

Share Document